Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2026-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Samil Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on business, audit, and internal accounting, as well as specific proposals for shareholder voting (financial statement approval, director appointments, etc.). It also includes detailed management information and financial data (balance sheets, income statements) as part of the 'Management Reference Materials' (경영참고사항) required for the meeting. This document is the official proxy statement/notice package provided to shareholders to inform them of the meeting and solicit their votes.
2026-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting date, agenda items (such as approval of financial statements, election of directors, etc.), and instructions for electronic voting. While it includes financial statements, these are provided as reference material for the shareholders' meeting, not as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-11 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Results of Disposal of Treasury Shares' (자기주식처분결과보고서) filed by Samil Pharmaceutical Co., Ltd. to the Financial Supervisory Service (FSS) in South Korea. It details the specific number of shares disposed of, the disposal price, the counterparty (Hyundai Pharm), and the impact on the company's treasury share holdings. This falls under the category of 'Transaction in Own Shares' (POS), which covers both share repurchases and disposals/sales of treasury shares.
2026-02-27 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing details the company's plan to sell or exchange its own shares, which falls under the category of 'Transaction in Own Shares' (POS).
2026-02-26 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Samil Pharmaceutical. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2026-02-26 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korean stock exchange (DART system) regarding a correction to a previously submitted 'Change in Sales or Profit/Loss Structure' report. It provides specific financial data (revenue, operating profit, net income) for the fiscal year 2025 compared to 2024. Since this is a formal regulatory disclosure of financial results (specifically a correction filing), it falls under the 'Regulatory Filings' category as it is a mandatory corporate announcement that does not constitute a full annual report or a standalone earnings release presentation.
2026-01-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.